We then analyzed the association between PRRC2A expression and well‐established gene mutations in CRC.[30] Interestingly, we found that high expression levels of PRRC2A were significantly associated with TP53 mutations in CRC patients (Figure S1C, Supporting Information). This evidence concerns the gene TP53 and colorectal carcinoma.